|
1
|
Kyle RA, Gertz MA, Witzig TE, Lust JA,
Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson
DR, et al: Review of 1027 patients with newly diagnosed multiple
myeloma. Mayo Clin Proc. 78:21–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kyle RA, Therneau TM, Rajkumar SV, Larson
DR, Plevak MF and Melton LJ III: Incidence of multiple myeloma in
olmsted county, minnesota. Cancer. 101:2667–2674. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi H, Chen Z, Xie J and Chen N: The
prevalence and management of multiple myeloma-induced kidney
disease in China. Kidney Dis. 1:235–240. 2016. View Article : Google Scholar
|
|
4
|
Rajkumar SV, Dimopoulos MA, Palumbo A,
Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E,
Richardson P, et al: International myeloma working group updated
criteria for the diagnosis of multiple myeloma. Lancet Oncol.
15:e538–e548. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Landgren O and Weiss BM: Patterns of
monoclonal gammopathy of undetermined significance and multiple
myeloma in various ethnic/racial groups: Support for genetic
factors in pathogenesis. Leukemia. 23:1691–1697. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Herrera GA and Sanders PW: Paraproteinemic
renal diseases that involve the tubulo-interstitium. Contrib
Nephrol. 153:105–115. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dimopoulos MA, Kastritis E, Rosinol L,
Bladé J and Ludwig H: Pathogenesis and treatment of renal failure
in multiple myeloma. Leukemia. 22:1485–1493. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tsakiris DJ, Stel VS, Finne P, Fraser E,
Heaf J, de Meester J, Schmaldienst S, Dekker F, Verrina E and Jager
KJ: Incidence and outcome of patients starting renal replacement
therapy for end-stage renal disease due to multiple myeloma or
light-chain deposit disease: An ERA-EDTA Registry study. Nephrol
Dial Transplant. 25:1200–1206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YC, Yeh HY, Wu JC, Haschler I, Chen
TJ and Wetter T: Taiwan's National health insurance research
database: Administrative health care database as study object in
bibliometrics. Scientometrics. 86:365–380. 2011. View Article : Google Scholar
|
|
10
|
Slee VN: The International classification
of diseases: Ninth revision (ICD-9). Ann Intern Med. 88:424–426.
1978. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lopes JA, Fernandes P, Jorge S, Gonçalves
S, Alvarez A, Costa e Silva Z, França C and Prata MM: Acute kidney
injury in intensive care unit patients: A comparison between the
RIFLE and the acute kidney injury network classifications. Crit
Care. 12:R1102008. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deyo RA, Cherkin DC and Ciol MA: Adapting
a clinical comorbidity index for use with ICD-9-CM administrative
databases. J Clin Epidemiol. 45:613–619. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Snozek CL, Katzmann JA, Kyle RA,
Dispenzieri A, Larson DR, Therneau TM, Melton LJ III, Kumar S,
Greipp PR, Clark RJ and Rajkumar SV: Prognostic value of the serum
free light chain ratio in newly diagnosed myeloma: Proposed
incorporation into the international staging system. Leukemia.
22:1933–1937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hutchison CA, Batuman V, Behrens J,
Bridoux F, Sirac C, Dispenzieri A, Herrera GA, Lachmann H and
Sanders PW: International Kidney Monoclonal Gammopathy Research
Group The pathogenesis and diagnosis of acute kidney injury in
multiple myeloma. Nat Rev Nephrol. 8:43–51. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakhuja V, Jha V, Varma S, Joshi K, Gupta
KL, Sud K and Kohli HS: Renal involvement in multiple myeloma: A
10-year study. Ren Fail. 22:465–477. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Walther C, Podoll AS and Finkel KW:
Treatment of acute kidney injury with cast nephropathy. Clin
Nephrol. 82:1–6. 2014.PubMed/NCBI
|
|
17
|
Yadav P, Cook M and Cockwell P: Current
trends of renal impairment in multiple myeloma. Kidney Dis.
1:241–257. 2016. View Article : Google Scholar
|
|
18
|
Knudsen LM, Hjorth M and Hippe E: Renal
failure in multiple myeloma: Reversibility and impact on the
prognosis. Nordic Myeloma Study Group. Eur J Haematol. 65:175–181.
2000. View Article : Google Scholar
|
|
19
|
Chen JH, Chung CH, Wang YC, Hsu SN, Huang
WY and Chien WC: Prevalence and mortality-related factors of
multiple myeloma in Taiwan. PLoS One. 11:e01672272016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Health NIo: US Renal Data System, USRDS
2010 Annual data report: Atlas of chronic kidney disease and
end-stage renal disease in the United States. National Institute of
Diabetes and Digestive and Kidney Diseases. 2010.
|
|
21
|
Kumar SK, Dispenzieri A, Lacy MQ, Gertz
MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, et
al: Continued improvement in survival in multiple myeloma: Changes
in early mortality and outcomes in older patients. Leukemia.
28:1122–1128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haynes RJ, Read S, Collins GP, Darby SC
and Winearls CG: Presentation and survival of patients with severe
acute kidney injury and multiple myeloma: 20-year experience from a
single centre. Nephrol Dial Transplantat. 25:419–426. 2010.
View Article : Google Scholar
|
|
23
|
International Myeloma Working Group
Criteria for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: A report of the
International Myeloma Working Group. Br J Haematol. 121:749–757.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Levey AS, Eckardt KU, Tsukamoto Y, Levin
A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, Lameire N and
Eknoyan G: Definition and classification of chronic kidney disease:
A position statement from kidney disease: Improving global outcomes
(KDIGO). Kidney Int. 67:2089–2100. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dimopoulos MA, Terpos E, Chanan-Khan A,
Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP,
Bladé J, et al: Renal impairment in patients with multiple myeloma:
A consensus statement on behalf of the International Myeloma
Working Group. J Clin Oncol. 28:4976–4984. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mehta RL, Kellum JA, Shah SV, Molitoris
BA, Ronco C, Warnock DG and Levin A: Acute Kidney Injury Network
Acute kidney injury network: Report of an initiative to improve
outcomes in acute kidney injury. Crit Care. 11:R31. 2007,
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hutchison CA, Bradwell AR, Cook M,
Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ,
Sampson P, et al: Treatment of acute renal failure secondary to
multiple myeloma with chemotherapy and extended high cut-off
hemodialysis. Clin J Am Soc Nephrol. 4:745–754. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hutchison CA, Cockwell P, Stringer S,
Bradwell A, Cook M, Gertz MA, Dispenzieri A, Winters JL, Kumar S,
Rajkumar SV, et al: Early reduction of serum-free light chains
associates with renal recovery in myeloma kidney. J Am Soc Nephrol.
22:1129–1136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zucchelli P, Pasquali S, Cagnoli L and
Ferrari G: Controlled plasma exchange trial in acute renal failure
due to multiple myeloma. Kidney Int. 33:1175–1180. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Johnson WJ, Kyle RA, Pineda AA, O'Brien PC
and Holley KE: Treatment of renal failure associated with multiple
myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch
Intern Med. 150:863–869. 1990.
|
|
31
|
Clark WF, Stewart AK, Rock GA, Sternbach
M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX and Churchill DN:
Canadian Apheresis Group Plasma exchange when myeloma presents as
acute renal failure: A randomized, controlled trial. Ann Intern
Med. 143:777–784. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gaskin G: MyEloma Renal Impairment Trial:
Adjunctive plasma exchange in patients with newly diagnosed
multiple myeloma and acute renal failure (MERIT). NCT00416897;
ISRCTN37161699.
|
|
33
|
Madore F: Plasmapheresis in cast
nephropathy: Yes or no? Curr Opin Nephrol Hypertens. 24:177–182.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hutchison CA, Cook M, Heyne N, Weisel K,
Billingham L, Bradwell A and Cockwell P: European trial of free
light chain removal by extended haemodialysis in cast nephropathy
(EuLITE): A randomised control trial. Trials. 9:552008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bridoux F and Fermand JP: Optimizing
treatment strategies in myeloma cast nephropathy: Rationale for a
randomized prospective trial. Adv Chronic Kidney Dis. 19:333–341.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Curti A, Schwarz A, Trachsler J, Tomonaga
Y and Ambühl PM: Therapeutic efficacy and cost effectiveness of
high cut-off dialyzers compared to conventional dialysis in
patients with cast nephropathy. PLoS One. 11:e01599422016.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Laforet M, Jourde-Chiche N, Haddad F,
Sallee M, Stoppa AM, Brunet P, Dussol B, Burtey S and Gondouin B:
Evolution in the treatment of multiple myeloma and impact on
dialysis independence: Data from a French cohort from 1999 to 2014.
Blood Cancer J. 6:e4092016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chow CC, Mo KL, Chan CK, Lo HK, Wong KS
and Chan JC: Renal Impairment in patients with multiple myeloma.
Hong Kong Med J. 9:78–82. 2003.PubMed/NCBI
|
|
39
|
Decourt A, Gondouin B, Delaroziere JC,
Brunet P, Sallée M, Burtey S, Dussol B, Ivanov V, Costello R,
Couchoud C and Jourde-Chiche N: Trends in survival and renal
recovery in patients with multiple myeloma or light-chain
amyloidosis on chronic dialysis. Clin J Am Soc Nephrol. 11:431–441.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen JH, Hsu SN, Huang TC, Wu YY, Lin C,
Chang PY, Chen YC and Ho CL: Prognostic significance of initial
serum albumin and 24 hour daily protein excretion before treatment
in multiple myeloma. PLoS One. 10:e01289052015. View Article : Google Scholar : PubMed/NCBI
|
